Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase 3 BOSTON study, once weekly selinexor, once weekly...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateos, Maria V., Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W., Leleu, Xavier, Hájek, Roman, Dimopoulos, Meletios A., Delimpasi, Sosana, Simonova, Maryana, Špička, Ivan, Pour, Ludĕk, Kriachok, Iryna, Pylypenko, Halyna, Doronin, Vadim, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan K., Sinha, Dinesh K., Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Badros, Ashraf Z., Anderson, Larry D., Bahlis, Nizar J., Cavo, Michele, Chai, Yi, Jeha, Jacqueline, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045319/
https://www.ncbi.nlm.nih.gov/pubmed/33849608
http://dx.doi.org/10.1186/s13045-021-01071-9

Ejemplares similares

Ejemplares similares